Intralytix awarded patent by USPTO for novel Shigella bacteriophages and their uses
07/14/2020 2 years ago

US Patent # 10,711,252 - Novel Shigella bacteriophage and uses thereof

Columbia, Maryland, USA. - July 14, 2020 - Intralytix, Inc. announced today that it has been issued a patent by the U.S. Patent & Trademark Office (USPTO) covering its Shigella bacteriophages and their various applications. The patent broadly relates to several bacteriophages with strong lytic potency against Shigella spp., and their various formulations. The patent also covers specific uses of these formulations, such as improving food safety and human health, including maintaining healthy gut microflora by modulating a mammal's microbiome and by reducing colonization by Shigella or levels of Shigella in the gut.

Dr. Alexander Sulakvelidze, Executive Vice President of Intralytix and one of the inventors listed on the patent, commented "Intralytix has always been one of the most innovative companies in the world in the field of bacteriophage technology, as evidenced by us having fifteen issued patents and several pending patent applications. This newly issued patent is yet another example of our inventive approach to bacteriophage technology. It supports the products and technology focused on helping solve morbidity and mortality due to Shigella, a very important bacterial pathogen responsible for approximately 125 million worldwide cases of shigellosis and 14,000 deaths annually, the majority in children under the age of five." Dr. Sulakvelidze added, "We were recently awarded a multimillion-dollar grant from the National Institutes of Health, to perform clinical trials using our Shigella phage preparation. This patent provides strong intellectual protection for that product and approach. We look forward to starting the clinical trials using this newly patented technology, and to bringing this product to market in the not too distant future."

About Intralytix Inc.

Intralytix, Inc. is a privately held company headquartered in Columbia, Maryland. The Company is focused on using its core bacteriophage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, oral care, cosmetic, and dietary supplements/probiotic applications. To learn more, please visit or contact Dr. Alexander Sulakvelidze (410-625-2533,